Adverse events in children and adolescents undergoing allergen immunotherapy for respiratory allergies-Report from the Allergen Immunotherapy Adverse Events Registry (ADER), a European Academy of Allergy and Clinical Immunology taskforce.
adverse events
allergen immunotherapy
real-life settings
risk factors
Journal
Clinical and translational allergy
ISSN: 2045-7022
Titre abrégé: Clin Transl Allergy
Pays: England
ID NLM: 101576043
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
21
04
2023
accepted:
26
04
2023
medline:
26
6
2023
pubmed:
26
6
2023
entrez:
26
6
2023
Statut:
ppublish
Résumé
Although it has been shown that allergen immunotherapy (AIT) is well-tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed. The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient- and AIT-related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated. A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in <30 min (87%). Respiratory and cutaneous symptoms were more frequent. Only 4 patients (0.47%) had severe AE (none after 6 weeks of maintenance). The risk of AE was higher in patients undergoing SCIT. AIT is safe and well tolerated in children and adolescents with respiratory allergies in real-life clinical practice. Though SCIT is more prone to AE compared to SLIT, overall severe reactions are rare and occur during build-up and early maintenance.
Sections du résumé
BACKGROUND
BACKGROUND
Although it has been shown that allergen immunotherapy (AIT) is well-tolerated in children, systematic and prospective surveillance of AIT safety in real life settings is needed.
METHODS
METHODS
The multinational Allergen Immunotherapy Adverse Events Registry (ADER) was designed to address AIT safety in real life clinical practice. Data on children ≤18 years old with respiratory allergies undergoing AIT were retrieved. Patient- and AIT-related features were collected and analyzed. The characteristics of adverse events (AE) and risk factors were evaluated.
RESULTS
RESULTS
A total of 851 patients, 11.3 ± 3.4 years old, with rhinitis only (47.6%); asthma and rhinitis (44.5%); asthma (7.9%), receiving 998 AIT courses were analyzed. Sublingual immunotherapy (SLIT) accounted for 51% of the courses. In 84.5% of patients only one AIT treatment was prescribed. Pollen was the most frequent sensitizer (57.1%), followed by mites (53.4%), molds (18.2%) and epithelia (16.7%). Local and systemic AEs were reported in 85 patients (9.9%). Most AEs (83.1%) were mild and occurred in <30 min (87%). Respiratory and cutaneous symptoms were more frequent. Only 4 patients (0.47%) had severe AE (none after 6 weeks of maintenance). The risk of AE was higher in patients undergoing SCIT.
CONCLUSIONS
CONCLUSIONS
AIT is safe and well tolerated in children and adolescents with respiratory allergies in real-life clinical practice. Though SCIT is more prone to AE compared to SLIT, overall severe reactions are rare and occur during build-up and early maintenance.
Identifiants
pubmed: 37357552
doi: 10.1002/clt2.12250
pmc: PMC10236500
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e12250Subventions
Organisme : Stallergenes
Organisme : European Academy of Allergy and Clinical Immunology
Investigateurs
Gerta Sinani
(G)
Eris Mesonjesi
(E)
Esmeralda Shehu
(E)
Etleva Qirko
(E)
Anila Nano
(A)
Valbona Martini
(V)
Enkelejda Gjata
(E)
Aferdita Sinani
(A)
Jana Sinani
(J)
Sybi Musollari
(S)
Alketa Bakiri
(A)
Diana Qama
(D)
Erjola Piluri
(E)
Fatmira Xhixha
(F)
Gilda Xhoxhi
(G)
Mirela Hitaj
(M)
Mehmet Hoxha
(M)
Alfred Priftanji
(A)
Dimitrov Zlatko
(D)
George Christoff
(G)
Silviya Novakova
(S)
Katya Noleva
(K)
Plamen Yakovliev
(P)
Ted Popov
(T)
Mirjana Turkalj
(M)
Damir Erceg
(D)
Asja Stipic
(A)
Mira Pevec
(M)
Branko Pevec
(B)
Sanja Popovic-Grle
(S)
Nikos Papadopoulos
(N)
Michael Makris
(M)
George Konstantinou
(G)
Dimitrios Mitsias
(D)
Xenofon Aggelidis
(X)
Christina Ciobanum
(C)
Ioana Agache
(I)
Florin Dan Popescu
(FD)
Irina Bukur
(I)
Ierima Augustin
(I)
Deleanu Dianna
(D)
Adriana Muntean
(A)
Vesna Tomic-Spiric
(V)
Rajica Stosovic
(R)
Mirjana Bogic
(M)
Dragana Tadic
(D)
Aleksandra Plavsic
(A)
Mitja Kosnik
(M)
Zeynep Mısırlıgil
(Z)
Dilsad Mungan
(D)
Moises A Z Calderon
(MAZ)
Informations de copyright
© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
Références
Allergy. 2021 Sep;76(9):2663-2672
pubmed: 33583050
Pediatr Allergy Immunol. 2017 Feb;28(1):60-70
pubmed: 27637414
Allergy. 2021 Nov;76(11):3504-3516
pubmed: 33655519
Clin Transl Allergy. 2014 Jul 21;4:22
pubmed: 25075276
Pediatr Allergy Immunol. 2012 Jun;23(4):300-6
pubmed: 22594930
Clin Exp Allergy. 2018 Jan;48(1):89-92
pubmed: 29108101
Clin Exp Allergy. 2021 Aug;51(8):985-988
pubmed: 34337808
Allergy. 2017 Mar;72(3):462-472
pubmed: 27718250
Eur Arch Otorhinolaryngol. 2021 Nov;278(11):4353-4360
pubmed: 33713192
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
J Allergy Clin Immunol. 2009 Jan;123(1):167-173.e7
pubmed: 19130937
Pediatr Allergy Immunol. 2018 May;29(3):267-274
pubmed: 29247543
Ann Allergy Asthma Immunol. 2017 Mar;118(3):276-282.e2
pubmed: 28284533
Ann Allergy Asthma Immunol. 2013 Apr;110(4):274-8, 278.e1
pubmed: 23535092
Allergy. 2018 Apr;73(4):765-798
pubmed: 28940458
Allergy. 2006;61 Suppl 82:1-20
pubmed: 16930249
Allergy Asthma Clin Immunol. 2020 Nov 2;16(1):93
pubmed: 33292437
J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55
pubmed: 21122901
Pediatr Allergy Immunol. 2017 Feb;28(1):18-29
pubmed: 27653623
Eur Ann Allergy Clin Immunol. 2015 Nov;47(6):211-7
pubmed: 26549339
Expert Rev Clin Immunol. 2015 Feb;11(2):233-45
pubmed: 25484197
J Allergy Clin Immunol. 2016 Feb;137(2):358-68
pubmed: 26853128
Eur Ann Allergy Clin Immunol. 2022 Mar;54(2):77-83
pubmed: 33728836
Allergy. 2012 Mar;67(3):302-11
pubmed: 22150126
Immunotherapy. 2020 Jan;12(1):75-87
pubmed: 31902260
Cochrane Database Syst Rev. 2020 Sep 14;9:CD011293
pubmed: 32926419
World Allergy Organ J. 2014 Mar 28;7(1):6
pubmed: 24679069
Allergy Asthma Proc. 2020 Mar 1;41(2):108-111
pubmed: 32122446
J Allergy Clin Immunol. 2012 Apr;129(4):929-34
pubmed: 22244595
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688
Allergy. 2017 Dec;72(12):1825-1848
pubmed: 28543086
Clin Exp Allergy. 2009 Oct;39(10):1569-74
pubmed: 19486027